EPHA4 and Stroke: One EphA4 inhibitor, the KYL peptide, has been studied extensively in models of neurological disorders, such as acute injuries including spinal cord injury and stroke and neurodegenerative disorders such as ALS and Alzheimer's disease (10, 11).